EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-Highly Expressed SLC17A9 and KCNH1 as Potential Prognostic Biomarkers and Therapeutic Targets in Clear Cell Renal Cell Carcinoma

Zongpan Ke, Zhiwang Tang, Deyun Shen, Yixun Liu, Yawei Shu, Xiangyu Mu, Zexuan Li, Ping Xiang, Bing Zhong, Xuechun Hu, Ruoyun Tan, Jun Xiao

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl38061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Zongpan Ke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, The Second Affiliate Hospital of Nanjing Medical University, 210011 Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science foundation of China, University Scientific research Project of the Education department of Anhui Province, Huai'an Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The vesicular nucleotide transporter Solute Carrier Family 17 Member 9 (SLC17A9) has recently been recognized as a significant modulator of oncogenic pathways, with its elevated expression levels being closely linked to the aggressiveness of clear cell renal cell carcinoma (ccRCC). A comprehensive understanding of the role of SLC17A9 and its associated protein markers presents substantial potential for the advancement of targeted therapeutic interventions.

Methods

Our study commenced with a comprehensive bioinformatics analysis to identify differentially expressed genes potentially associated with ccRCC. Leveraging The Cancer Genome Atlas (TCGA) database, we predicted the clinical relevance of these cancer-associated genes and validated their expression profiles through multiple experimental methodologies. Functional assays were conducted to assess the impact of these genes on renal cancer cell lines. Additionally, we generated cell lines overexpressing oncogenes and identified downstream targets through RNA sequencing, followed by mechanistic exploration of their interactions. Finally, bioinformatics tools were subsequently employed to assess the diagnostic and prognostic significance of these genes in patients with ccRCC.

Results

The bioinformatics analysis revealed SLC17A9 as a highly expressed oncogene in ccRCC, serving as a robust prognostic marker. Experimental validation demonstrated that SLC17A9 promotes ccRCC cell growth, proliferation, and migration. Lentivirus-based experiments revealed Potassium Voltage-Gated Channel Subfamily H Member 1 (KCNH1) as a downstream target regulated by SLC17A9 (p < 0.05). Database analysis further confirmed KCNH1’s oncogenic role in ccRCC, with significant implications for patient survival. Notably, SLC17A9 and KCNH1 collaboratively drive the initiation and progression of renal cancer. Elevated expression of SLC17A9 and KCNH1 correlates with poorer prognosis (p < 0.001), whereas lower expression levels are associated with favorable outcomes in ccRCC patients. These findings highlight SLC17A9 and KCNH1 as critical biomarkers and potential therapeutic targets in ccRCC.

Conclusion

SLC17A9 and KCNH1 serve as critical prognostic biomarkers in ccRCC, with SLC17A9 driving tumor progression through KCNH1 regulation. Their upregulated expression predicts poor clinical outcomes, while reduced levels correlate with improved survival, highlighting their dual role as therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorHumansPrognosisCell Line, TumorGene Expression Regulation, NeoplasticCell ProliferationComputational BiologyCell MovementFemaleEther-A-Go-Go Potassium Channels

Stichwörter der Autor:innen

KCNH1 potassium channelSLC17A9 protein, humanbiomarkers, tumorcarcinoma, renal celldisease progression

Substanzen

Biomarkers, TumorKCNH1 protein, humanEther-A-Go-Go Potassium Channels

Autor:innen und Institutionen

  • Urology Department, The Second Affiliate Hospital of Nanjing Medical University, 210011 Nanjing, Jiangsu, China.
  • Urology Department, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China.
  • Urology Department, The Affiiated Huaian No.1 People's Hospital of Nanjing Medical University, 223300 Huai'an, Jiangsu, China.
  • Urology Department, The First Affiliated Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China.

Förderung

  • National Natural Science foundation of China
  • University Scientific research Project of the Education department of Anhui Province
  • Huai'an Natural Science Foundation
  • Huai’an Natural Science Foundation

Zitieren

APA

Ke, Z., Tang, Z., Shen, D., Liu, Y., Shu, Y., Mu, X., Li, Z., Xiang, P., Zhong, B., Hu, X., Tan, R., & Xiao, J. (2025). Co-Highly Expressed SLC17A9 and KCNH1 as Potential Prognostic Biomarkers and Therapeutic Targets in Clear Cell Renal Cell Carcinoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl38061

Vancouver

Ke Z, Tang Z, Shen D, Liu Y, Shu Y, Mu X, et al. Co-Highly Expressed SLC17A9 and KCNH1 as Potential Prognostic Biomarkers and Therapeutic Targets in Clear Cell Renal Cell Carcinoma. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl38061

BibTeX
@article{Ke2025,
  author = {Ke, Zongpan and Tang, Zhiwang and Shen, Deyun and Liu, Yixun and Shu, Yawei and Mu, Xiangyu and Li, Zexuan and Xiang, Ping and Zhong, Bing and Hu, Xuechun and Tan, Ruoyun and Xiao, Jun},
  title = {Co-Highly Expressed SLC17A9 and KCNH1 as Potential Prognostic Biomarkers and Therapeutic Targets in Clear Cell Renal Cell Carcinoma},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl38061}
}
Kostenlos starten →